Management Team   BOD   SAB   CAB   About Metabolic Diseases
  Home > About  

Metabolex discovers and develops novel therapeutics to treat type 2 diabetes and related metabolic disorders. It is our goal to bring to the patient breakthrough medicines that improve quality of life. Our deep understanding of the biology of these diseases has enabled us to build a robust pipeline of proprietary product candidates.
Arhalofenate (MBX-102) is a novel oral small molecule uricosuric agent that is an attractive new therapy for the treatment of gout. Arhalofenate demonstrates robust, dose-dependent reductions in serum uric acid in patients with mild-to-moderate renal insuffiency or on concomitant aspirin therapy. In addition to and, importantly, controlling hyperucemia, arhalofenate also lowers glucose, triglycerides, and markers of inflammation. Thus, arhalofenate is a potential best-in-class uric acid lowering agent that not only corrects the hyperuricemia asociated with gout, but also addresses other aspects of metabolic syndrome.
MBX-2982 is a potential first-in-class treatment for type 2 diabetes that targets G protein-coupled receptor 119 (GPR 119), a receptor that interacts with bioactive lipids known to stimulate glucose-dependent insulin secretion. MBX-2982 is a potent GPR 119 agonist that has completed three Phase 1 trials and is currently in Phase 2 testing. In all studies to date, MBX-2982 was rapidly absorbed, lowered glucose excursions, and was well-tolerated with no serious adverse events.
MBX-8025 is our product candidate for treating mixed dyslipidemia, a group of disorders that includes elevated LDL cholesterol and/or triglycerides, and low levels of HDL cholesterol. We recently completed a thorough Phase 2 proof-of-concept study that showed MBX-8025 effectively addresses each of the lipid abnormalities associated with mixed dyslipidemia and also showed potential efficacy at treating other metabolic disorders.
Our strategy is to discover and develop promising therapies for metabolic diseases to address significant unmet medical needs in large markets, developing them through proof-of-concept studies and then collaborating with companies through late-stage clinical trials and commercialization to maximize the value of our compounds.
To execute our strategy, we have assembled a management team with deep experience in developing promising drugs and technologies, including former executives at Syntex, Roche, Merck, Pfizer and Sugen.